

07th January, 2025

To,

| | |
|---|--|
| The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i> | National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i> |
|---|--|

Sub: Disclosure under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”)

Dear Sir(s)/Madam,

This is to inform you that as part of the Company’s operational strategy, the Company shall sell and transfer its undertaking being the manufacturing facility of the Company situated at Plot No. A-17, Phase II, Special Economic Zone, Pithampur, Dhar, Madhya Pradesh, 454775, India (“**Facility**”) alongwith all rights, title and interest in the leasehold land, factory building, assets and liabilities etc. with respect to the said Facility to M/s. Rubicon Research Limited (*formerly known as Rubicon Research Private Limited*) (“**Rubicon**”) on a slump sale basis pursuant to the Business Transfer Agreement dated 06 January, 2025 executed between the Company and Rubicon.

The details as required under SEBI LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are enclosed herewith as Annexure I.

Kindly take the same on records.

Sincerely,
For **Alkem Laboratories Limited**

Manish Narang
President – Legal, Company Secretary & Compliance Officer

Encl: a/a

Annexure I

| | |
|---|---|
| 1) Manufacturing unit/ facility proposed to be sold | Transfer of the undertaking, being the manufacturing facility of the Company situated at Plot No. A-17, Phase II, Special Economic Zone, Pithampur, Dhar, Madhya Pradesh, 454775, India on a slump sale basis |
| 2) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year | <p>Amount of turnover: NA</p> <p>% of Total Turnover: NA</p> <p>Networth: INR 133.5 crores (Since it is a manufacturing unit, the value of Net block of Property, Plant & Equipment including CWIP has been mentioned)</p> |
| 3) Date on which the agreement for sale has been entered into | The Business Transfer Agreement has been entered into on 06 January, 2025. |
| 4) The expected date of completion of sale | 05 th June, 2025. |
| 5) Consideration received from such sale | INR 149 crores/- (Rupees One Hundred & Forty Nine Crores only), subject to changes in Net Current Assets. |
| 6) Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/ group companies. If yes, details thereof; | <p>Rubicon is a public limited Company incorporated under the provisions of the Companies Act, 1956 on 06th May, 1999. It is engaged in the business of development, manufacture, distribution and sale of pharmaceutical formulations.</p> <p>Rubicon does not belong to the promoter/ promoter group of the Company.</p> |
| 7) Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length” | The said transaction does not fall within the purview of related party transactions. |

| | |
|--|--|
| <p>8) Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations</p> | <p>Not applicable</p> |
| <p>9) name of the entity(ies) forming part of the slump sale, details in brief such as size, turnover etc.;</p> | <p>Please see information disclosed in serial nos. 1-5 above.</p> |
| <p>10) whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;</p> | <p>Please see information disclosed in serial no 7 above.</p> |
| <p>11) area of business of the entity(ies);</p> | <p>The Company is engaged in research and development, manufacturing, distribution, marketing and sales of pharmaceuticals and other healthcare products.</p> <p>Rubicon is engaged in the business of development, manufacture, distribution and sale of pharmaceutical formulations.</p> |
| <p>12) rationale for slump sale;</p> | <p>Ongoing initiative of networking strategy and optimization of manufacturing facilities.</p> |
| <p>13) in case of cash consideration – amount or otherwise share exchange ratio;</p> | <p>Cash consideration as specified in serial nos. 5 above.</p> |
| <p>14) brief details of change in shareholding pattern (if any) of listed entity</p> | <p>There will not be any change in the shareholding pattern of the Company pursuant to the slump sale.</p> |